Serum Soluble CD163 and its association with various disease parameters in patients with systemic sclerosis
European Journal of Rheumatology • 2016
Publication Information
Authors
Waleed Ahmed Salah Eldeen Hassan1, Eman Abd Elaleem Baraka1, Basant Mohammed Elnady1,
Tahany Mahmoud Gouda2, Nehad Fouad3
Keywords
Systemic sclerosis, soluble CD 163, macrophages, modified Rodnan skin score
Journal
European Journal of Rheumatology
Publisher
Not Available
Volume
3
Issue
95-100
Pages
6
publication.type
International
Paper Link
Open Link
Supplementary Materials
Not Available
Abstract
Abstract
Objective: Cluster of differentiation 163 (CD163) is a receptor that binds haptoglobin-hemoglobin complexes and is mainly expressed
on macrophages and monocytes. As a result of shedding, the extracellular portion of CD163 circulates in the blood as a
soluble CD163 (sCD163). This study aimed to measure serum sCD163 levels in patients with systemic sclerosis (SSc) and to assess its
association with the clinical, laboratory, and radiological features of the disease.
Material and Methods: We measured serum sCD163 levels in 24 patients with SSc and in 30 healthy controls. Complete history of
the patients was recorded and thorough clinical, rheumatological, and dermatological examinations were performed. For SSc, the
skin thickness score was scored according to the modified Rodnan skin score method and pulmonary involvement was assessed in
all patients using high-resolution computed tomography and by performing pulmonary function tests.
Results: The mean serum sCD163 levels in patients with diffuse and limited SSc (61.64±19.57 and 60.8±21.43 ng/mL, respectively)
demonstrated a highly statistically significant increase compared with the mean serum levels in healthy controls (36.97±16.37 ng/
mL) (p
Objective: Cluster of differentiation 163 (CD163) is a receptor that binds haptoglobin-hemoglobin complexes and is mainly expressed
on macrophages and monocytes. As a result of shedding, the extracellular portion of CD163 circulates in the blood as a
soluble CD163 (sCD163). This study aimed to measure serum sCD163 levels in patients with systemic sclerosis (SSc) and to assess its
association with the clinical, laboratory, and radiological features of the disease.
Material and Methods: We measured serum sCD163 levels in 24 patients with SSc and in 30 healthy controls. Complete history of
the patients was recorded and thorough clinical, rheumatological, and dermatological examinations were performed. For SSc, the
skin thickness score was scored according to the modified Rodnan skin score method and pulmonary involvement was assessed in
all patients using high-resolution computed tomography and by performing pulmonary function tests.
Results: The mean serum sCD163 levels in patients with diffuse and limited SSc (61.64±19.57 and 60.8±21.43 ng/mL, respectively)
demonstrated a highly statistically significant increase compared with the mean serum levels in healthy controls (36.97±16.37 ng/
mL) (p
Staff Members - Benha University